Hello Everyone,
As per my understanding, the OECD (Q)SAR Toolbox is primarily designed for chemical hazard assessment; however, it can also be very useful for toxicity prediction in pharmaceutical applications.
The software is both expert rule-based and statistically driven. However, it requires interpretation and manual operation by a subject-matter expert, typically a toxicologist. It incorporates multiple models such as CASE Ultra and Leadscope, but the outputs need to be interpreted carefully to ensure appropriate use.
Being a non-expert, I find the tool quite difficult to use. Additionally, it contains multiple profilers for different toxicity endpoints (e.g., Ames mutagenicity, in vivo studies, etc.). While it provides valuable information such as structural alerts and functional groups, individual profilers alone may not always be reliable, as suggested in the literature.
Overall, the toolbox appears to be more comprehensive than standalone tools like CASE Ultra; however, it is challenging for non-experts and can be time-consuming to operate. Moreover, it does not provide a single consolidated prediction report—rather, it generates outputs that require expert review and interpretation.
In this context, I would appreciate your guidance on how this tool can be used more effectively and efficiently to generate reliable toxicity predictions. Additionally, I would need confirmation whether predictions generated using this tool (standalone) are acceptable to pharmaceutical regulatory authorities such as USFDA, EMA, EDQM, and ANVISA.
I am enclosing few articles in support of the above discussion.
Thanks,
Gautam G. Halder
Validation of OECD QSAR Toolbox profilers for genotoxicity assessment of.pdf (3.4 MB)
Case ultra vs OECD GTI assesment, CT 2025.pdf (618.5 KB)